Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: Richard Query who wrote (1465)	5/4/1998 9:15:00 AM
From: jad	Read Replies (1) \| Respond to of 1693

This may have been a small reason why: QUIDEL Initiates the Sale of Two New Rapid Tests for the Detection of hCG SAN DIEGO, May 4 /PRNewswire/ -- QUIDEL Corporation (Nasdaq: QDEL - news) today announced that it has commenced marketing of two new rapid tests for use in the clinical laboratory market that detect hCG, the hormone produced during pregnancy. The two new tests are: 1) QuickVue(R) SemiQ(TM) hCG Combo 2) CARDS(R) QS(R) hCG - Serum/Urine Test QUIDEL will now have two new hCG tests that are easy to use and offer the higher sensitivity required by the clinical laboratory. This market segment, in which Quidel is currently not the market leader, is estimated to be a $20 million market opportunity. Because of the need for ease-of-use coupled with the highest possible low- end sensitivity of hCG tests in the clinical lab market, these two new tests make them excellent choices for clinical use where the determination of an unknown pregnancy can prevent unnecessary procedures from being performed on the mother that could be harmful to the fetus.